Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial

AIMS: In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by 34%, and CV death by 38%, with an early separation of the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Leiter, Lawrence A., Zinman, Bernard, Sharma, Abhinav, Mattheus, Michaela, Fitchett, David, George, Jyothis, Ofstad, Anne Pernille, Kosiborod, Mikhail N., Wanner, Christoph, Inzucchi, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318423/
https://www.ncbi.nlm.nih.gov/pubmed/34132492
http://dx.doi.org/10.1002/ehf2.13374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318423/
https://www.ncbi.nlm.nih.gov/pubmed/34132492
http://dx.doi.org/10.1002/ehf2.13374

Ejemplares similares